Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies

Abstract

A decreased incidence of nephrotoxicity provides evidence of a real clinical benefit to patient management in patients with hematologic malignancies. The TDM for vancomycin therapy in this high-risk population has been shown to be a cost-effective procedure.